Table 2.
PCPs (n = 981) and Oncologists (n = 1,125) Reporting Awareness of LEs for Each Chemotherapy Agent*
| LE | Doxorubicin |
Cyclophosphamide |
Paclitaxel |
Oxaliplatin |
Fluorouacil |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCPs (%) | Oncologists (%) | P | PCPs (%) | Oncologists (%) | P | PCPs (%) | Oncologists (%) | P | PCPs (%) | Oncologists (%) | P | PCPs (%) | Oncologists (%) | P | |
| Peripheral neuropathy | 8 | 1 | < .001 | 17 | 3 | < .001 | 27 | 97 | < .001 | 22 | 97 | < .001 | 13 | 8 | < .001 |
| Pulmonary fibrosis | 8 | 1 | < .001 | 13 | 21 | < .001 | 6 | 5 | NS | 9 | 5 | < .001 | 2 | 2 | NS |
| Cardiac dysfunction | 55 | 95 | < .001 | 7 | 8 | NS | 6 | 5 | NS | 1 | 0 | NS | 7 | 22 | < .001 |
| Premature menopause | 7 | 67 | < .001 | 15 | 71 | < .001 | 13 | 31 | < .001 | 2 | 15 | < .001 | 3 | 15 | < .001 |
| Secondary malignancies | 5 | 48 | < .001 | 17 | 62 | < .001 | 3 | 4 | NS | 2 | 4 | .008 | 6 | 4 | .03 |
| Do not know | 36 | 0.5 | < .001 | 51 | 6 | < .001 | 56 | 1 | < .001 | 71 | 2 | < .001 | 66 | 27 | < .001 |
NOTE. For doxorubicin, main LE is cardiac dysfunction; for paclitaxel and oxaliplatin, main LE is peripheral neuropathy; for cyclophosphamide, main LEs are premature menopause and secondary malignancies (indicated by bold font).
Abbreviations: LE, late or long-term effect; PCP, primary care provider.
*
Total of 96 respondents (4%) skipped section (PCPs, n = 91; oncologists, n = 5).